Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	COVID Reference, 5th edition, 486 pages Free download

Lung Cancer

Free Subscription Articles published in Cancer Retrieve available abstracts of 120 articles: HTML format

Single Articles

November 2020
1. NARAYAN AK, Gupta Y, Little BP, Shepard JO, et al
   Lung cancer screening eligibility and use with low-dose computed tomography: Results from the 2018 Behavioral Risk Factor Surveillance System cross-sectional survey.
   Cancer. 2020 Nov 18. doi: 10.1002/cncr.33322.
   PubMed     Abstract available
   
   
   October 2020
2. WANG M, Liang H, Wang W, Zhao S, et al
   Immune-related adverse events of a PD-(L)1 inhibitor plus chemotherapy versus a PD-(L)1 inhibitor alone in first-line treatment for advanced non-small cell lung cancer: A meta-analysis of randomized control trials.
   Cancer. 2020 Oct 29. doi: 10.1002/cncr.33270.
   PubMed     Abstract available
   
   
   
3. PATHAK R, De Lima Lopes G, Yu H, Aryal MR, et al
   Comparative efficacy of chemoimmunotherapy versus immunotherapy for advanced non-small cell lung cancer: A network meta-analysis of randomized trials.
   Cancer. 2020 Oct 29. doi: 10.1002/cncr.33269.
   PubMed     Abstract available
   
   
   September 2020
4. QIAN JM, Martin AM, Martin K, Hammoudeh L, et al
   Response rate and local recurrence after concurrent immune checkpoint therapy and radiotherapy for non-small cell lung cancer and melanoma brain metastases.
   Cancer. 2020 Sep 14. doi: 10.1002/cncr.33196.
   PubMed     Abstract available
   
   
   
5. BORGHAEI H, Langer CJ, Paz-Ares L, Rodriguez-Abreu D, et al
   Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non-small cell lung cancer without tumor PD-L1 expression: A pooled analysis of 3 randomized controlled trials.
   Cancer. 2020 Sep 11. doi: 10.1002/cncr.33142.
   PubMed     Abstract available
   
   
   
6. NAZHA B, Goyal S, Chen Z, Engelhart A, et al
   Efficacy and safety of immune checkpoint blockade in self-identified black patients with advanced non-small cell lung cancer.
   Cancer. 2020 Sep 9. doi: 10.1002/cncr.33141.
   PubMed     Abstract available
   
   
   
7. FRIEDLAENDER A, Drilon A, Banna GL, Peters S, et al
   The METeoric rise of MET in lung cancer.
   Cancer. 2020 Sep 5. doi: 10.1002/cncr.33159.
   PubMed     Abstract available
   
   
   August 2020
8. ZHANG EW, Dagogo-Jack I, Kuo A, Rooney MM, et al
   Association between circulating tumor DNA burden and disease burden in patients with ALK-positive lung cancer.
   Cancer. 2020 Aug 5. doi: 10.1002/cncr.33118.
   PubMed     Abstract available
   
   
   July 2020
9. FRIEDES C, Mai N, Fu W, Hu C, et al
   Isolated progression of metastatic lung cancer: Clinical outcomes associated with definitive radiotherapy.
   Cancer. 2020 Jul 30. doi: 10.1002/cncr.33109.
   PubMed     Abstract available
   
   
   
10. DURM GA, Jabbour SK, Althouse SK, Liu Z, et al
    A phase 2 trial of consolidation pembrolizumab following concurrent chemoradiation for patients with unresectable stage III non-small cell lung cancer: Hoosier cancer research network LUN 14-179.
    Cancer. 2020 Jul 22. doi: 10.1002/cncr.33083.
    PubMed     Abstract available
    
    
    
11. STEINDL A, Yadavalli S, Gruber KA, Seiwald M, et al
    Neurological symptom burden impacts survival prognosis in patients with newly diagnosed non-small cell lung cancer brain metastases.
    Cancer. 2020 Jul 17. doi: 10.1002/cncr.33085.
    PubMed     Abstract available
    
    
    
12. PRINTZ C
    New guidance for treating patients with lung cancer and COVID-19.
    Cancer. 2020;126:3173.
    PubMed    
    
    
    
13. WANG N, Mengersen K, Tong S, Kimlin M, et al
    Global, regional, and national burden of lung cancer and its attributable risk factors, 1990 to 2017.
    Cancer. 2020 Jul 10. doi: 10.1002/cncr.33078.
    PubMed     Abstract available
    
    
    June 2020
14. PARK S, Shim J, Mortimer PGS, Smith SA, et al
    Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy.
    Cancer. 2020 Jun 25. doi: 10.1002/cncr.33048.
    PubMed     Abstract available
    
    
    
15. ALAHMADI A, Dowlati A
    Slicing and dicing small cell lung cancer to improve trial outcomes.
    Cancer. 2020 Jun 25. doi: 10.1002/cncr.33047.
    PubMed    
    
    
    May 2020
16. MACK PC, Banks KC, Espenschied CR, Burich RA, et al
    Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non-small cell lung cancer: Analysis of over 8000 cases.
    Cancer. 2020 May 4. doi: 10.1002/cncr.32876.
    PubMed     Abstract available
    
    
    March 2020
17. LEE J, Kim HS, Lee B, Kim HK, et al
    Genomic landscape of acquired resistance to third-generation EGFR tyrosine kinase inhibitors in EGFR T790M-mutant non-small cell lung cancer.
    Cancer. 2020 Mar 10. doi: 10.1002/cncr.32809.
    PubMed     Abstract available
    
    
    
18. PASSARO A, Malapelle U, Attili I, de Marinis F, et al
    Overcoming resistance to osimertinib in non-small cell lung cancer: Hopes, doubts, and in-between.
    Cancer. 2020 Mar 10. doi: 10.1002/cncr.32810.
    PubMed    
    
    
    
19. PETRILLO LA, El-Jawahri A, Nipp RD, Lichtenstein MRL, et al
    Performance status and end-of-life care among adults with non-small cell lung cancer receiving immune checkpoint inhibitors.
    Cancer. 2020 Mar 6. doi: 10.1002/cncr.32782.
    PubMed     Abstract available
    
    
    February 2020
20. PRINTZ C
    New research finds lung cancer screening guidelines are insufficient for firefighters.
    Cancer. 2020;126:692-693.
    PubMed    
    
    
    
21. PRINTZ C
    A more effective approach to lung cancer screening?: Researchers have developed a new risk prediction model to help inform patients and their physicians whether they should undergo lung cancer screening and, if so, when.
    Cancer. 2020;126:691-692.
    PubMed    
    
    
    
22. TAKAHAMA T, Azuma K, Shimokawa M, Takeda M, et al
    Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
    Cancer. 2020 Feb 5. doi: 10.1002/cncr.32749.
    PubMed     Abstract available
    
    
    January 2020
23. ZHANG H, Qian G, Zong D, Fan S, et al
    Overcoming acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib by combining osimertinib with the histone deacetylase inhibitor panobinostat (LBH589).
    Cancer. 2020 Jan 30. doi: 10.1002/cncr.32744.
    PubMed     Abstract available
    
    
    
24. LEUNG M, Freidin MB, Freydina DV, Von Crease C, et al
    Blood-based circulating tumor DNA mutations as a diagnostic and prognostic biomarker for lung cancer.
    Cancer. 2020 Jan 30. doi: 10.1002/cncr.32699.
    PubMed     Abstract available
    
    
    
25. WEISS JM, Pennell N, Deal AM, Morgenzstern D, et al
    Nab-paclitaxel in older patients with non-small cell lung cancer who have developed disease progression after platinum-based doublet chemotherapy.
    Cancer. 2020 Jan 14. doi: 10.1002/cncr.32573.
    PubMed     Abstract available
    
    
    
26. YOUN B, Trikalinos NA, Mor V, Wilson IB, et al
    Real-world use and survival outcomes of immune checkpoint inhibitors in older adults with non-small cell lung cancer.
    Cancer. 2020 Jan 14. doi: 10.1002/cncr.32624.
    PubMed     Abstract available
    
    
    
27. AGGARWAL C, Langer CJ
    Systemic therapy for elderly patients with non-small cell lung cancer: Where do we stand in 2019?
    Cancer. 2020 Jan 14. doi: 10.1002/cncr.32625.
    PubMed    
    
    
    
28. IWAMA E, Sakai K, Hidaka N, Inoue K, et al
    Longitudinal monitoring of somatic genetic alterations in circulating cell-free DNA during treatment with epidermal growth factor receptor-tyrosine kinase inhibitors.
    Cancer. 2020;126:219-227.
    PubMed     Abstract available
    
    
    December 2019
29. LI Y, Zang H, Qian G, Owonikoko TK, et al
    ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small-cell lung cancer cells to osimertinib.
    Cancer. 2019 Dec 10. doi: 10.1002/cncr.32655.
    PubMed     Abstract available
    
    
    November 2019
30. PAPADIMITRAKOPOULOU VA, Han JY, Ahn MJ, Ramalingam SS, et al
    Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer.
    Cancer. 2019 Nov 26. doi: 10.1002/cncr.32503.
    PubMed     Abstract available
    
    
    
31. PRINTZ C
    The number of patients with lung cancer eligible for a clinical trial could double with broader enrollment criteria.
    Cancer. 2019;125:3907.
    PubMed    
    
    
    
32. HU X, Bao Y, Xu YJ, Zhu HN, et al
    Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses.
    Cancer. 2019 Nov 12. doi: 10.1002/cncr.32586.
    PubMed     Abstract available
    
    
    
33. BODOR JN, Boumber Y, Borghaei H
    Biomarkers for immune checkpoint inhibition in non-small cell lung cancer (NSCLC).
    Cancer. 2019 Nov 6. doi: 10.1002/cncr.32468.
    PubMed     Abstract available
    
    
    October 2019
34. LITZELMAN K, Reblin M, McDowell HE, DuBenske LL, et al
    Trajectories of social resource use among informal lung cancer caregivers.
    Cancer. 2019 Oct 18. doi: 10.1002/cncr.32545.
    PubMed     Abstract available
    
    
    September 2019
35. WANG S, Lai S, von Itzstein MS, Yang L, et al
    Type and case volume of health care facility influences survival and surgery selection in cases with early-stage non-small cell lung cancer.
    Cancer. 2019 Sep 10. doi: 10.1002/cncr.32377.
    PubMed     Abstract available
    
    
    August 2019
36. LIN JJ, Gainor JF
    Time to tackle the blood-brain barrier in HER2-mutant lung cancer.
    Cancer. 2019 Aug 30. doi: 10.1002/cncr.32460.
    PubMed    
    
    
    
37. OFFIN M, Feldman D, Ni A, Myers ML, et al
    Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers.
    Cancer. 2019 Aug 30. doi: 10.1002/cncr.32461.
    PubMed     Abstract available
    
    
    
38. HUO J, Hong YR, Turner K, Bian J, et al
    Utilization pattern and service settings of palliative care for patients with metastatic non-small-cell lung cancer.
    Cancer. 2019 Aug 26. doi: 10.1002/cncr.32478.
    PubMed     Abstract available
    
    
    
39. FISET PO, Labbe C, Young K, Craddock KJ, et al
    Anaplastic lymphoma kinase 5A4 immunohistochemistry as a diagnostic assay in lung cancer: A Canadian reference testing center's results in population-based reflex testing.
    Cancer. 2019 Aug 7. doi: 10.1002/cncr.32422.
    PubMed     Abstract available
    
    
    
40. KHOZIN S, Miksad RA, Adami J, Boyd M, et al
    Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non-small cell lung cancer.
    Cancer. 2019 Aug 5. doi: 10.1002/cncr.32383.
    PubMed     Abstract available
    
    
    July 2019
41. WAN X, Luo X, Tan C, Zeng X, et al
    First-line atezolizumab in addition to bevacizumab plus chemotherapy for metastatic, nonsquamous non-small cell lung cancer: A United States-based cost-effectiveness analysis.
    Cancer. 2019 Jul 9. doi: 10.1002/cncr.32368.
    PubMed     Abstract available
    
    
    
42. CHEN Y, Zhang R, Wang L, Correa AM, et al
    Tumor characteristics associated with engraftment of patient-derived non-small cell lung cancer xenografts in immunocompromised mice.
    Cancer. 2019 Jul 9. doi: 10.1002/cncr.32366.
    PubMed     Abstract available
    
    
    
43. WANG H, Ou Q, Li D, Qin T, et al
    Genes associated with increased brain metastasis risk in non-small cell lung cancer: Comprehensive genomic profiling of 61 resected brain metastases versus primary non-small cell lung cancer (Guangdong Association Study of Thoracic Oncology 1036).
    Cancer. 2019 Jul 9. doi: 10.1002/cncr.32372.
    PubMed     Abstract available
    
    
    June 2019
44. HADDAD R, Concha-Benavente F, Blumenschein G Jr, Fayette J, et al
    Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
    Cancer. 2019 Jun 27. doi: 10.1002/cncr.32190.
    PubMed     Abstract available
    
    
    May 2019
45. MARSHALL CH, Al-Mallah MH, Dardari Z, Brawner CA, et al
    Cardiorespiratory fitness and incident lung and colorectal cancer in men and women: Results from the Henry Ford Exercise Testing (FIT) cohort.
    Cancer. 2019 May 6. doi: 10.1002/cncr.32085.
    PubMed     Abstract available
    
    
    April 2019
46. MORGENSZTERN D, Ko A, O'Brien M, Ong TJ, et al
    Association between depth of response and survival in patients with advanced-stage non-small cell lung cancer treated with first-line chemotherapy.
    Cancer. 2019 Apr 1. doi: 10.1002/cncr.32114.
    PubMed     Abstract available
    
    
    March 2019
47. PRINTZ C
    Study projects a 43% increase in lung cancer mortality among women: New research suggests that, among women, strides in reducing global deaths from breast cancer could be tempered by rising lung cancer deaths. However, according to experts, the projec
    Cancer. 2019;125:831-832.
    PubMed    
    
    
    
48. GILL HS, Ramalingam SS
    A new standard of care for patients with surgically unresectable stage III non-small cell lung cancer.
    Cancer. 2019 Mar 2. doi: 10.1002/cncr.31996.
    PubMed    
    
    
    
49. SINGH N, Baldi M, Kaur J, Muthu V, et al
    Timing of folic acid/vitamin B12 supplementation and hematologic toxicity during first-line treatment of patients with nonsquamous non-small cell lung cancer using pemetrexed-based chemotherapy: The PEMVITASTART randomized trial.
    Cancer. 2019 Mar 2. doi: 10.1002/cncr.32028.
    PubMed     Abstract available
    
    
    February 2019
50. BLOM EF, Ten Haaf K, Arenberg DA, de Koning HJ, et al
    Treatment capacity required for full-scale implementation of lung cancer screening in the United States.
    Cancer. 2019 Feb 27. doi: 10.1002/cncr.32026.
    PubMed     Abstract available
    
    
    January 2019
51. DELLA CORTE CM, Gay CM, Byers LA
    Beyond chemotherapy: Emerging biomarkers and therapies as small cell lung cancer enters the immune checkpoint era.
    Cancer. 2019 Jan 8. doi: 10.1002/cncr.31863.
    PubMed    
    
    
    
52. PRINTZ C
    Currently recommended lung cancer screening guidelines may be insufficient for high-risk minorities.
    Cancer. 2019;125:10-11.
    PubMed    
    
    
    
53. PRINTZ C
    First Person: Paul Bunn, Jr, MD, FASCO: An icon in the oncology world, he has led major cancer organizations and clinical trials and launched the University of Colorado Cancer Center.
    Cancer. 2019;125:9-10.
    PubMed    
    
    
    December 2018
54. NAZHA B, Owonikoko TK
    The clinical conundrum of managing relapsed small cell lung cancer.
    Cancer. 2018 Dec 18. doi: 10.1002/cncr.31849.
    PubMed    
    
    
    
55. NG TL, Liu Y, Dimou A, Patil T, et al
    Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
    Cancer. 2018 Dec 11. doi: 10.1002/cncr.31871.
    PubMed     Abstract available
    
    
    
56. MCFARLAND DC, Shaffer K, Breitbart W, Rosenfeld B, et al
    C-reactive protein and its association with depression in patients receiving treatment for metastatic lung cancer.
    Cancer. 2018 Dec 6. doi: 10.1002/cncr.31859.
    PubMed     Abstract available
    
    
    
57. AHN MJ, Tsai CM, Shepherd FA, Bazhenova L, et al
    Osimertinib in patients with T790M mutation-positive, advanced non-small cell lung cancer: Long-Term follow-up from a pooled analysis of 2 phase 2 studies.
    Cancer. 2018 Dec 4. doi: 10.1002/cncr.31891.
    PubMed     Abstract available
    
    
    November 2018
58. AHVENAINEN TV, Makinen NM, von Nandelstadh P, Vahteristo MEA, et al
    Loss of ATRX/DAXX expression and alternative lengthening of telomeres in uterine leiomyomas.
    Cancer. 2018 Nov 13. doi: 10.1002/cncr.31754.
    PubMed     Abstract available
    
    
    
59. MORGENSZTERN D, Cobo M, Ponce Aix S, Postmus PE, et al
    ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).
    Cancer. 2018 Nov 1. doi: 10.1002/cncr.31779.
    PubMed     Abstract available
    
    
    
60. GOLDBERG SB, Herbst RS
    Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?
    Cancer. 2018 Nov 1. doi: 10.1002/cncr.31681.
    PubMed    
    
    
    October 2018
61. STINCHCOMBE TE, Fan W, Schild SE, Vokes EE, et al
    A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients.
    Cancer. 2018 Oct 21. doi: 10.1002/cncr.31813.
    PubMed     Abstract available
    
    
    September 2018
62. HATA A, Katakami N, Kaji R, Yokoyama T, et al
    Afatinib Plus Bevacizumab Combination After Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Multicenter, Single-Arm, Phase 2 Trial (ABC Study).
    Cancer. 2018 Sep 7. doi: 10.1002/cncr.31678.
    PubMed     Abstract available
    
    
    
63. 
    Declining lung cancer death rates lag for women in 2 US hot spots.
    Cancer. 2018;124:3467.
    PubMed    
    
    
    August 2018
64. 
    Neoadjuvant Nivolumab Safe, Led to Major Response Rates in Resectable Lung Cancer.
    Cancer. 2018;124:3283.
    PubMed    
    
    
    June 2018
65. PATEL JD, Chmura SJ
    Is immune checkpoint inhibition part of standard therapy for stage III non-small cell lung cancer?
    Cancer. 2018 Jun 15. doi: 10.1002/cncr.31557.
    PubMed    
    
    
    May 2018
66. GOLDWASSER F, Vinant P, Aubry R, Rochigneux P, et al
    Timing of palliative care needs reporting and aggressiveness of care near the end of life in metastatic lung cancer: A national registry-based study.
    Cancer. 2018 May 9. doi: 10.1002/cncr.31536.
    PubMed     Abstract available
    
    
    April 2018
67. SPIGEL DR, Burris HA 3rd, Greco FA, Shih KC, et al
    Erlotinib plus either pazopanib or placebo in patients with previously treated advanced non-small cell lung cancer: A randomized, placebo-controlled phase 2 trial with correlated serum proteomic signatures.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31290.
    PubMed     Abstract available
    
    
    
68. ARBOUR KC, Riely GJ
    Improving therapy for patients with epidermal growth factor receptor-mutant lung cancer.
    Cancer. 2018 Apr 12. doi: 10.1002/cncr.31289.
    PubMed    
    
    
    
69. PRINTZ C
    Lung cancer screening based on personal risk may save more lives.
    Cancer. 2018;124:1315.
    PubMed    
    
    
    March 2018
70. HIRSCH FR, Sequist LV, Gore I, Mooradian M, et al
    Long-term safety and survival with gefitinib in select patients with advanced non-small cell lung cancer: Results from the US IRESSA Clinical Access Program (ICAP).
    Cancer. 2018 Mar 26. doi: 10.1002/cncr.31313.
    PubMed     Abstract available
    
    
    February 2018
71. SPIGEL DR, Hainsworth JD, Joseph MJ, Shipley DL, et al
    Randomized phase 2 trial of pemetrexed, pemetrexed/bevacizumab, and pemetrexed/carboplatin/bevacizumab in patients with stage IIIB/IV non-small cell lung cancer and an Eastern Cooperative Oncology Group performance status of 2.
    Cancer. 2018 Feb 16. doi: 10.1002/cncr.30986.
    PubMed     Abstract available
    
    
    January 2018
72. CASSIDY RJ, Zhang X, Switchenko JM, Patel PR, et al
    Health care disparities among octogenarians and nonagenarians with stage III lung cancer.
    Cancer. 2018 Jan 8. doi: 10.1002/cncr.31077.
    PubMed     Abstract available
    
    
    December 2017
73. TANDBERG DJ, Tong BC, Ackerson BG, Kelsey CR, et al
    Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review.
    Cancer. 2017 Dec 19. doi: 10.1002/cncr.31196.
    PubMed     Abstract available
    
    
    
74. RICHARDS TB, Henley SJ, Puckett MC, Weir HK, et al
    Lung cancer survival in the United States by race and stage (2001-2009): Findings from the CONCORD-2 study.
    Cancer. 2017;123 Suppl 24:5079-5099.
    PubMed     Abstract available
    
    
    
75. ASSI HI, Kamphorst AO, Moukalled NM, Ramalingam SS, et al
    Immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Cancer. 2017 Dec 6. doi: 10.1002/cncr.31105.
    PubMed     Abstract available
    
    
    
76. KATAKAMI N, Uchino J, Yokoyama T, Naito T, et al
    Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: Results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04).
    Cancer. 2017 Dec 4. doi: 10.1002/cncr.31128.
    PubMed     Abstract available
    
    
    
77. NIXON NA, Khan OF, Imam H, Tang PA, et al
    Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014.
    Cancer. 2017;123:4672-4679.
    PubMed     Abstract available
    
    
    
78. MANSOUR MSI, Seidal T, Mager U, Baigi A, et al
    Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
    Cancer. 2017;125:908-917.
    PubMed     Abstract available
    
    
    November 2017
79. HAHN EJ, Rayens MK, Wiggins AT, Gan W, et al
    Lung cancer incidence and the strength of municipal smoke-free ordinances.
    Cancer. 2017 Nov 28. doi: 10.1002/cncr.31142.
    PubMed     Abstract available
    
    
    
80. SPIEGEL ML, Goldman JW, Wolf BR, Nameth DJ, et al
    Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges.
    Cancer. 2017 Nov 10. doi: 10.1002/cncr.31056.
    PubMed     Abstract available
    
    
    October 2017
81. STOY SP, Rosen L, Mueller J, Murgu S, et al
    Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy.
    Cancer. 2017 Oct 20. doi: 10.1002/cncy.21941.
    PubMed     Abstract available
    
    
    
82. CHAD-FRIEDMAN E, Coleman S, Traeger LN, Pirl WF, et al
    Psychological distress associated with cancer screening: A systematic review.
    Cancer. 2017;123:3882-3894.
    PubMed     Abstract available
    
    
    
83. HEYMANN JJ, Bulman WA, Swinarski D, Pagan CA, et al
    Programmed death-ligand 1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens.
    Cancer. 2017 Oct 12. doi: 10.1002/cncy.21937.
    PubMed     Abstract available
    
    
    
84. SULLIVAN DR, Ganzini L, Lapidus JA, Hansen L, et al
    Improvements in hospice utilization among patients with advanced-stage lung cancer in an integrated health care system.
    Cancer. 2017 Oct 10. doi: 10.1002/cncr.31047.
    PubMed     Abstract available
    
    
    
85. CASSIDY RJ, Zhang X, Patel PR, Shelton JW, et al
    Next-generation sequencing and clinical outcomes of patients with lung adenocarcinoma treated with stereotactic body radiotherapy.
    Cancer. 2017;123:3681-3690.
    PubMed     Abstract available
    
    
    September 2017
86. PILLAI RN, Behera M, Owonikoko TK, Kamphorst AO, et al
    Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature.
    Cancer. 2017 Sep 28. doi: 10.1002/cncr.31043.
    PubMed     Abstract available
    
    
    
87. ARBOUR KC, Kris MG, Riely GJ, Ni A, et al
    Twice weekly pulse and daily continuous-dose erlotinib as initial treatment for patients with epidermal growth factor receptor-mutant lung cancers and brain metastases.
    Cancer. 2017 Sep 21. doi: 10.1002/cncr.30990.
    PubMed     Abstract available
    
    
    
88. YANG D, Zhang X, Powell CA, Ni J, et al
    Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study.
    Cancer. 2017 Sep 20. doi: 10.1002/cncr.31020.
    PubMed     Abstract available
    
    
    
89. LAMBROS L, Guibourg B, Uguen A
    Costs of ALK, ROS1, EGFR, and KRAS testing in non-small cell lung cancer: About different strategies in France.
    Cancer. 2017 Sep 11. doi: 10.1002/cncy.21919.
    PubMed    
    
    
    
90. TRONCONE G
    Reply to Costs of ALK, ROS1, EGFR, and KRAS testing in non-small cell lung cancer: About different strategies in France.
    Cancer. 2017 Sep 11. doi: 10.1002/cncy.21918.
    PubMed    
    
    
    
91. PRINTZ C
    Nivolumab improves survival for patients with advanced lung cancer.
    Cancer. 2017;123:3211.
    PubMed    
    
    
    
92. SADETZKI S, Chetrit A, Freedman LS, Hakak N, et al
    Cancer risk among Holocaust survivors in Israel-A nationwide study.
    Cancer. 2017;123:3335-3345.
    PubMed     Abstract available
    
    
    August 2017
93. MOORE KN, Borghaei H, O'Malley DM, Jeong W, et al
    Phase 1 dose-escalation study of mirvetuximab soravtansine (IMGN853), a folate receptor alpha-targeting antibody-drug conjugate, in patients with solid tumors.
    Cancer. 2017;123:3080-3087.
    PubMed     Abstract available
    
    
    
94. MEDHANIE GA, Fedewa SA, Adissu H, DeSantis CE, et al
    Cancer incidence profile in sub-Saharan African-born blacks in the United States: Similarities and differences with US-born non-Hispanic blacks.
    Cancer. 2017;123:3116-3124.
    PubMed     Abstract available
    
    
    
95. JAGAI JS, Messer LC, Rappazzo KM, Gray CL, et al
    County-level cumulative environmental quality associated with cancer incidence.
    Cancer. 2017;123:2901-2908.
    PubMed     Abstract available
    
    
    
96. HUNG YP, Lovitch SB, Qian X
    Histiocytic sarcoma: New insights into FNA cytomorphology and molecular characteristics.
    Cancer. 2017;125:604-614.
    PubMed     Abstract available
    
    
    
97. CAPPELLESSO R, Galasso M, Nicole L, Dabrilli P, et al
    miR-130A as a diagnostic marker to differentiate malignant mesothelioma from lung adenocarcinoma in pleural effusion cytology.
    Cancer. 2017;125:635-643.
    PubMed     Abstract available
    
    
    July 2017
98. PISAPIA P, Lozano MD, Vigliar E, Bellevicine C, et al
    ALK and ROS1 testing on lung cancer cytologic samples: Perspectives.
    Cancer. 2017 Jul 25. doi: 10.1002/cncy.21899.
    PubMed     Abstract available
    
    
    
99. PILLAI RN, Behera M, Berry LD, Rossi MR, et al
    HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium.
    Cancer. 2017 Jul 25. doi: 10.1002/cncr.30869.
    PubMed     Abstract available
    
    
    
100. RWIGEMA JM, Verma V, Lin L, Berman AT, et al
     Prospective study of proton-beam radiation therapy for limited-stage small cell lung cancer.
     Cancer. 2017 Jul 5. doi: 10.1002/cncr.30870.
     PubMed     Abstract available
     
     
     June 2017
101. GOLDSTEIN DA, Bilal U, Prasad V
     Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?
     Cancer. 2017 Jun 29. doi: 10.1002/cncr.30868.
     PubMed    
     
     
     
102. GAINOR JF
     Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?
     Cancer. 2017 Jun 16. doi: 10.1002/cncy.21882.
     PubMed    
     
     
     
103. PRINTZ C
     Lung cancer screening rates remain very low among current and former smokers.
     Cancer. 2017;123:2189.
     PubMed    
     
     
     
104. LILO MT, Allison DB, Younes BK, Cui M, et al
     The critical role of EBUS-TBNA cytology in the staging of mediastinal lymph nodes in lung cancer patients: A correlation study with positron emission tomography findings.
     Cancer. 2017 Jun 13. doi: 10.1002/cncy.21886.
     PubMed     Abstract available
     
     
     
105. ZAKOWSKI MF
     Analytic inquiry: Molecular testing in lung cancer.
     Cancer. 2017;125.
     PubMed     Abstract available
     
     
     
106. BAUM JE, Zhang P, Hoda RS, Geraghty B, et al
     Accuracy of next-generation sequencing for the identification of clinically relevant variants in cytology smears in lung adenocarcinoma.
     Cancer. 2017;125:398-406.
     PubMed     Abstract available
     
     
     May 2017
107. MINO-KENUDSON M
     Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice.
     Cancer. 2017 May 4. doi: 10.1002/cncy.21873.
     PubMed    
     
     
     
108. TARHINI AA, Rafique I, Floros T, Tran P, et al
     Phase 1/2 study of rilotumumab (AMG 102), a hepatocyte growth factor inhibitor, and erlotinib in patients with advanced non-small cell lung cancer.
     Cancer. 2017 May 4. doi: 10.1002/cncr.30717.
     PubMed     Abstract available
     
     
     
109. CHUANG JC, Neal JW
     The persistent promise of combining HGF/MET and EGFR inhibition in non-small cell lung cancer.
     Cancer. 2017 May 4. doi: 10.1002/cncr.30718.
     PubMed    
     
     
     April 2017
110. ERSEK M, Miller SC, Wagner TH, Thorpe JM, et al
     Association between aggressive care and bereaved families' evaluation of end-of-life care for veterans with non-small cell lung cancer who died in Veterans Affairs facilities.
     Cancer. 2017 Apr 17. doi: 10.1002/cncr.30700.
     PubMed     Abstract available
     
     
     
111. SABRA MM, Sherman EJ, Tuttle RM
     Tumor volume doubling time of pulmonary metastases predicts overall survival and can guide the initiation of multikinase inhibitor therapy in patients with metastatic, follicular cell-derived thyroid carcinoma.
     Cancer. 2017 Apr 3. doi: 10.1002/cncr.30690.
     PubMed     Abstract available
     
     
     March 2017
112. ZHANG L, Jiang T, Li X, Wang Y, et al
     Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
     Cancer. 2017 Mar 27. doi: 10.1002/cncr.30677.
     PubMed     Abstract available
     
     
     
113. SUN B, Brooks ED, Komaki RU, Liao Z, et al
     7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
     Cancer. 2017 Mar 27. doi: 10.1002/cncr.30693.
     PubMed     Abstract available
     
     
     
114. KEAM B, Kim MK, Choi Y, Choi SJ, et al
     Optimal timing of influenza vaccination during 3-week cytotoxic chemotherapy cycles.
     Cancer. 2017;123:841-848.
     PubMed     Abstract available
     
     
     February 2017
115. VERMA V, Shostrom VK, Kumar SS, Zhen W, et al
     Multi-institutional experience of stereotactic body radiotherapy for large (>/=5 centimeters) non-small cell lung tumors.
     Cancer. 2017;123:688-696.
     PubMed     Abstract available
     
     
     
116. SAAB J, Hoda RS, Narula N, Hoda SA, et al
     Diagnostic yield of cytopathology in evaluating pericardial effusions: Clinicopathologic analysis of 419 specimens.
     Cancer. 2017;125:128-137.
     PubMed     Abstract available
     
     
     
117. WANG H, Hoda RS, Faquin W, Rossi ED, et al
     FNA biopsy of secondary nonlymphomatous malignancies in salivary glands: A multi-institutional study of 184 cases.
     Cancer. 2017;125:91-103.
     PubMed     Abstract available
     
     
     January 2017
118. VELIZHEVA NP, Rechsteiner MP, Wong CE, Zhong Q, et al
     Cytology smears as excellent starting material for next-generation sequencing-based molecular testing of patients with adenocarcinoma of the lung.
     Cancer. 2017;125:30-40.
     PubMed     Abstract available
     
     
     December 2016
119. BISHOP JA, French CA, Ali SZ
     Cytopathologic features of NUT midline carcinoma: A series of 26 specimens from 13 patients.
     Cancer. 2016;124:901-908.
     PubMed     Abstract available
     
     
     June 2016
120. DROOGER JC, van Tinteren H, de Groot SM, Ten Tije AJ, et al
     A randomized phase 2 study exploring the role of bevacizumab and a chemotherapy-free approach in HER2-positive metastatic breast cancer: The HAT study (BOOG 2008-2003), a Dutch Breast Cancer Research Group trial.
     Cancer. 2016 Jun 17. doi: 10.1002/cncr.30141.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: